GLSI News and Press, Greenwich LifeSciences Inc. From 07/11/22

The stock market has been under unimaginable selling pressure for the last several quarters. The stock market sell-off has been exasperated by the Fed's actions to reduce inflation. This lays out a vast buying opportunity that only the most skilled investors/traders will take adva...

Greenwich LifeSciences (NASDAQ:GLSI) plans to resume its existing stock repurchase program; ~$4.5M remained available under the current program. As of March 31, 2022, the company had 12.95M shares of common stock outstanding. For further details see: Greenwich LifeSciences to resume sto...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced today it would resume its existing Stock Repurchase Program. Under the repurchase program previously authorized by ...

FDA review of manufacturing plans and pharmacy procedures associated with a recently placed clinical hold on the FLAMINGO-01 phase III clinical trial is underway with formal feedback from the FDA expected shortly. Greenwich is prepared to address FDA manufacturing and pharmacy procedu...

Shares of Greenwich LifeSciences, Inc. are trading near their lowest levels since the stock exploded upward in December 2020 in what was an illustrative example of an inefficient market. A still-pending Phase 3 study launch for its only asset in the treatment of breast cancer that was...

Greenwich LifeSciences is a stock relatively new to the market and lesser-known, as it became public in September of 2020. Not long after, the stock skyrocketed over 1000% on early data that the company's GP2 treatment reduced breast cancer recurrences to zero. While this is still...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that Sne...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the foll...

The Phase III clinical trial, Flamingo-01, is now registered on clinicaltrials.gov with identifier NCT05232916 (view here ), where more details about the trial design and a preliminary listing of the initial clinical sites can be found Company management will be attending ...

Greenwich LifeSciences (GLSI +24.4%) is enjoying substantial gains Thursday, continuing a winning streak that began on Tuesday. From the close of trading Monday through Wednesday's close, shares rose ~11%. Year to date through Wednesday's close, shares are down 16%. The recent ...